<DOC>
	<DOCNO>NCT00491257</DOCNO>
	<brief_summary>This study design generate clinical data outline Note Guidance harmonization requirement influenza vaccine marketing authorization European Medicines Agency . The objective trial : - To determine immunogenicity , inactivate , split-virion influenza vaccine Northern Hemisphere ( NH ) 2007-2008 formulation term requirement Committee Human Medicinal Products ( CHMP ) Note Guidance ( NfG ) CPMP/BWP/214/96 . - To describe safety inactivate , split-virion influenza vaccine , NH 2007-2008 formulation .</brief_summary>
	<brief_title>A Study Immunogenicity Safety 2007-2008 Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Orthomyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 60 year ( i.e . day 61st birthday ) 61 year ( day 61st birthday ) day inclusion Provision sign informed consent Able attend schedule visit comply trial procedure For woman childbearing potential : avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior vaccination , least 4 week vaccination Exclusion Criteria : For woman childbearing potential , known pregnancy positive urine pregnancy test Visit 1 Febrile illness ( temperature &gt; = 37.5Â°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment Breastfeeding woman Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity egg protein , chicken protein , vaccine component , history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion Investigator Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure Receipt blood bloodderived product past 3 month , might interfere assessment immune response Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine 3 week follow trial vaccination Previous vaccination influenza previous 6 month Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular vaccination Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B surface antigen Hepatitis C seropositivity Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviridae Infections</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Split-virion influenza vaccine</keyword>
</DOC>